Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover

10. November 2026 aktualisiert von: Wenjing Zhou, RenJi Hospital

A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover, Including EQ-TIPS, EQ-5D-Y-5L, EQ-5D-5L With Sleep and Fatigue Bolt-ons, and the EQ-HWB-9

This study aims to address critical gaps in the measurement of health-related quality of life (HRQoL) in children under the age of five by conducting a comprehensive psychometric validation of the EQ-TIPS instrument, including both 3-level and 5-level versions. We will conduct a longitudinal study using both quantitative and qualitative methods to assess the feasibility, face validity, known-groups validity, test-retest reliability, and responsiveness of both EQ-TIPS-3L and EQ-TIPS-5L in children aged 0-48 months. For children aged 25-48 months, we will also examine the comparability and potential transition between EQ-TIPS-5L and the proxy version of EQ-5D-Y-5L. In addition, we aim to explore spillover effects on family carers by evaluating the psychometric performance, such as known-groups validity, test-retest reliability, and responsiveness of two newly developed EQ-5D-5L bolt-on items (sleep and fatigue) and the EQ-HWB-9. A total of 450 participants will be recruited from three tertiary hospitals in China across three health condition groups: acute illnesses (n=180), chronic conditions (n=180), and healthy controls (n=90), with an approximately balanced distribution across age groups and disease severity levels. The survey questionnaires will include two parts: 1) Child section: EQ-TIPS-3L, EQ-TIPS-5L, proxy EQ VAS, EQ-5D-Y-5L proxy version 1 (only for children aged 25-48 months), a 5-grade overall health assessment (OHA) proxy version, QQ-10 questionnaire, and children's demographic information; 2) Carer section: carers' EQ-5D-5L with sleep and fatigue bolt-ons, carers' EQ VAS, carers' EQ-HWB-9, and carers' demographic information. Each clinical condition is selected for its high prevalence and clinical relevance in early childhood, as well as its suitability for stratifying health status by severity. Additionally, to assess face validity, carers will complete the QQ-10 questionnaire after completing the EQ-TIPS questionnaire to provide structured feedback on the clarity, relevance, and acceptability of EQ-TIPS. Findings will contribute essential evidence to support the use of EQ-TIPS in early childhood HRQoL assessment and of the EQ-5D-5L bolt-ons and EQ-HWB-9 in evaluating caregiver spillover effects. The study data will be shared with the EuroQol Group to support future development and application of these instruments.

Studienübersicht

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

450

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Sekunde bis 4 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population will consist of 450 children aged 0-48 months and their primary family carers recruited from three tertiary hospitals in China. Participants will be enrolled into three groups: acute illnesses (pneumonia and diarrhoea, n=180), chronic conditions (haematological malignancies and asthma, n=180), and healthy controls (n=90). Recruitment will aim for balanced representation across age groups (0-24 and 25-48 months) and disease severity levels. Children with illnesses will be recruited from outpatient clinics and inpatient departments, while healthy controls will be recruited during routine physical examinations. Primary family carers will serve as proxy respondents for child health assessments and complete questionnaires assessing their own health and well-being.

Beschreibung

Inclusion Criteria:

  • -Children aged 0-48 months at enrolment.
  • Children diagnosed with pneumonia, acute diarrhoea, haematological malignancies, or asthma; or healthy children without known medical conditions attending routine physical examinations.
  • Availability of a primary family carer (parent, grandparent, or legal guardian) who has primarily cared for the child during the preceding month, including supervision of daily activities and health-related care.
  • The primary family carer accompanies the child during the outpatient visit, inpatient admission, or routine physical examination.
  • The primary family carer is able to understand the study information and provides written informed consent.

Exclusion Criteria:

  • Children older than 48 months at enrolment.
  • Primary family carers unable to read or understand Chinese.
  • Primary family carers with cognitive impairments that prevent questionnaire completion.
  • Absence of written informed consent.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Acute Illness Group

Children aged 0-48 months diagnosed with acute illnesses, including pneumonia (n=90) and acute diarrhoea (n=90). Participants will be recruited across different disease severity levels. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, while also reporting their own health and well-being.

This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study.

Chronic Illness Group

Children aged 0-48 months diagnosed with chronic conditions, including haematological malignancies (n=90) and asthma (n=90). Participants will represent different levels of disease severity. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, alongside assessments of their own health and caregiver spillover effects

This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study.

Healthy Control Group

Group/Cohort Description:

Age-matched healthy children aged 0-48 months (n=90), with no known medical conditions at the time of assessment, recruited during routine physical examinations. Their primary family carers will complete the same proxy-reported child health and caregiver health-related quality of life assessments as those in the illness groups.

This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Known-Groups Validity of EQ-TIPS-3L and EQ-TIPS-5L
Zeitfenster: Baseline

Known-groups validity will be evaluated by comparing EQ-TIPS-3L and EQ-TIPS-5L level sum scores (LSS) across predefined clinical severity categories and overall health assessment (OHA) categories. Cohen's d and relative efficiency based on ANOVA F-statistics will be calculated to assess the instruments' discriminatory ability.

Baseline
Test-Retest Reliability of EQ-TIPS-3L and EQ-TIPS-5L
Zeitfenster: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Test-retest reliability will be evaluated among children whose health status remains stable between baseline and follow-up, as determined by unchanged clinical severity and overall health assessment (OHA). Intraclass correlation coefficients (ICCs) will be calculated for EQ-TIPS level sum scores (LSS), and Gwet's agreement coefficients will be calculated for individual dimensions.

Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
Responsiveness of EQ-TIPS-3L and EQ-TIPS-5L to Changes in Child Health
Zeitfenster: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Responsiveness will be evaluated by changes in EQ-TIPS-3L and EQ-TIPS-5L scores between baseline and follow-up among children classified as improved, stable, or deteriorated based on clinical indicators and overall health assessment (OHA). Standardised effect size (SES), standardised response mean (SRM), and Paretian Classification of Health Change (PCHC) will be calculated.

Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Face Validity and Acceptability of EQ-TIPS-3L and EQ-TIPS-5L
Zeitfenster: Baseline

Face validity and acceptability will be assessed using the QQ-10 questionnaire completed by family carers. Quantitative responses will evaluate perceived value, clarity, relevance, and acceptability. Open-ended responses will undergo thematic content analysis to identify concerns regarding comprehensiveness, redundancy, and questionnaire burden.

Baseline
Comparative Psychometric Performance of EQ-TIPS-3L and EQ-TIPS-5L
Zeitfenster: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

EQ-TIPS-3L and EQ-TIPS-5L will be compared in terms of missing responses, response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to health change. Ceiling effects will be assessed using the proportion of children reporting no problems across all dimensions.

Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
Psychometric Performance of EQ-5D-5L With Sleep and Fatigue Bolt-Ons and EQ-HWB-9 in Family Carers
Zeitfenster: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Caregiver outcomes will be evaluated using EQ-5D-5L with sleep and fatigue bolt-on items and EQ-HWB-9. Analyses will assess response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to changes in child health. Regression analyses will explore associations with child disease severity, caregiving time, and caregiver burden.

Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

10. Dezember 2026

Primärer Abschluss (Geschätzt)

10. Dezember 2027

Studienabschluss (Geschätzt)

9. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

10. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren